FDA-cleared profile

syngo Application Software

Siemens Medical Solutions, USA, Inc. · Radiological images; modality varies or is not specified in FDA list · FDA-cleared (510(k))

Authorized purpose: syngo Application Software provides real-time viewing, image manipulation, 3D visualization, communication, and storage of medical images and data on exchange media for diagnostic viewing, post-processing, and viewing or post-processing during interventional procedures. It may run on a stand-alone workstation, send and receive DICOM data over a network, be deployed on Siemens angiography systems, and be combined with fluoroscopy or radiographic systems for image-guided surgery and interventional cardiology, electrophysiology, oncology, radiology, and neuroradiology.

Clinical role
Real-time image viewing, manipulation, 3D visualization, communication, storage, and interventional image fusion or navigation support.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Anatomy represented in supported medical images and interventional procedures
Key limitation
Keep in mind: Configured modalities, OEM options, procedures, hardware, and local workflow determine the available functions; the software does not replace qualified professional interpretation or procedural control.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: syngo Application Software provides real-time viewing, image manipulation, 3D visualization, communication, and storage of medical images and data on exchange media for diagnostic viewing, post-processing, and viewing or post-processing during interventional procedures. It may run on a stand-alone workstation, send and receive DICOM data over a network, be deployed on Siemens angiography systems, and be combined with fluoroscopy or radiographic systems for image-guided surgery and interventional cardiology, electrophysiology, oncology, radiology, and neuroradiology.
  • Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Anatomy represented in supported medical images and interventional procedures Input: Medical images and data received from supported imaging systems, exchange media, and DICOM network connections.
  • Who uses it?Intended users: Physicians and trained healthcare professionals responsible for diagnostic or interventional image review.
  • What does the software produce?Output: Displayed, manipulated, post-processed, fused, communicated, and stored medical images and procedure-support information.
  • What is its most important limitation?Key limitation: Configured modalities, OEM options, procedures, hardware, and local workflow determine the available functions; the software does not replace qualified professional interpretation or procedural control.

Clinical takeaway. Clinical role: syngo Application Software provides real-time viewing, image manipulation, 3D visualization, communication, and storage of medical images and data on exchange media for diagnostic viewing, post-processing, and viewing or post-processing during interventional procedures. It may run on a stand-alone workstation, send and receive DICOM data over a network, be deployed on Siemens angiography systems, and be combined with fluoroscopy or radiographic systems for image-guided surgery and interventional cardiology, electrophysiology, oncology, radiology, and neuroradiology.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports verification and validation testing; for the added feature syngo TrueFusion, validation used 28 phantom test data sets, with multiple measurements from different C-arm directions by a board certified cardiologist. Acceptance: mean deviation shall not exceed 3mm with a standard deviation not exceeding 2mm. Reported mean (standard deviation) at C-arm positions A, B, C: experiment 1, 2,92mm (1,29mm), 2,59mm (1,50mm), 2,31mm (1,62mm); experiment 2, 2,76mm (1,31mm), 2,57mm (1,69mm), 2,13mm (1,48mm). Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
syngo Application Software provides real-time viewing, image manipulation, 3D visualization, communication, and storage of medical images and data on exchange media for diagnostic viewing, post-processing, and viewing or post-processing during interventional procedures. It may run on a stand-alone workstation, send and receive DICOM data over a network, be deployed on Siemens angiography systems, and be combined with fluoroscopy or radiographic systems for image-guided surgery and interventional cardiology, electrophysiology, oncology, radiology, and neuroradiology.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Real-time image viewing, manipulation, 3D visualization, communication, storage, and interventional image fusion or navigation support.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Medical images and data received from supported imaging systems, exchange media, and DICOM network connections.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Displayed, manipulated, post-processed, fused, communicated, and stored medical images and procedure-support information.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Diagnostic imaging workstations, operating rooms, and interventional cardiology, radiology, oncology, or neuroradiology workflows.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Physicians and trained healthcare professionals responsible for diagnostic or interventional image review.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Configured modalities, OEM options, procedures, hardware, and local workflow determine the available functions; the software does not replace qualified professional interpretation or procedural control.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports verification and validation testing; for the added feature syngo TrueFusion, validation used 28 phantom test data sets, with multiple measurements from different C-arm directions by a board certified cardiologist. Acceptance: mean deviation shall not exceed 3mm with a standard deviation not exceeding 2mm. Reported mean (standard deviation) at C-arm positions A, B, C: experiment 1, 2,92mm (1,29mm), 2,59mm (1,50mm), 2,31mm (1,62mm); experiment 2, 2,76mm (1,31mm), 2,57mm (1,69mm), 2,13mm (1,48mm). Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The modifications described in this Premarket Notification were supported with verification and validation testing." … "Subject Device Modification: Added software feature “syngo TrueFusion” 2. Objective or Purpose of Test: Validate syngo TrueFusion results 3. Explanation of sample size and Statistical Methods: 28 phantom test data sets". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports verification and validation testing; for the added feature syngo TrueFusion, validation used 28 phantom test data sets, with multiple measurements from different C-arm directions by a board certified cardiologist. Acceptance: mean deviation shall not exceed 3mm with a standard deviation not exceeding 2mm. Reported mean (standard deviation) at C-arm positions A, B, C: experiment 1, 2,92mm (1,29mm), 2,59mm (1,50mm), 2,31mm (1,62mm); experiment 2, 2,76mm (1,31mm), 2,57mm (1,69mm), 2,13mm (1,48mm). Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The modifications described in this Premarket Notification were supported with verification and validation testing." … "Subject Device Modification: Added software feature “syngo TrueFusion” 2. Objective or Purpose of Test: Validate syngo TrueFusion results 3. Explanation of sample size and Statistical Methods: 28 phantom test data sets". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K170747 FDA evidence package for syngo Application Software

  • DesignFDA 510(k) software validation, clinical-image review, and non-clinical substantial-equivalence evidence for the syngo Application Software configuration.
  • PopulationAnatomy represented in supported medical images and interventional procedures
  • Scopeexact submission
  • Tested versionsyngo Application Software (VD20) configuration described in K170747
  • IndependenceSponsor or vendor study

K170747

The broad multimodality and interventional scope is configuration-dependent; the FDA package does not establish every OEM option or procedure at every site.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K170747 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Medical images and data received from supported imaging systems, exchange media, and DICOM network connections.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) K170747: syngo Application Software

  2. Routing

    Source context, not route validation: The FDA package explicitly describes DICOM network send and receive, stand-alone diagnostic or reporting workstations, Siemens angiography systems, and combination with fluoroscopy or radiographic systems.

    Scope: Exact FDA submission. This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) K170747: syngo Application Software

  3. AI processing

    Source context, not route validation: The FDA package describes stand-alone diagnostic review, post-processing, and reporting workstations; network configuration; Siemens angiography-system deployment; and combinations with fluoroscopy or radiographic systems. Current hosting, service, security, availability, and site configuration remain unverified.

    Scope: Exact FDA submission. This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 · FDA 510(k) K170747: syngo Application Software

  4. Returned objects

    Source context, not route validation: Displayed, manipulated, post-processed, fused, communicated, and stored medical images and procedure-support information.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) K170747: syngo Application Software

  5. Viewer/worklist/report

    Unresolved route: Displayed, manipulated, post-processed, fused, communicated, and stored medical images and procedure-support information.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) K170747: syngo Application Software

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA package describes stand-alone diagnostic review, post-processing, and reporting workstations; network configuration; Siemens angiography-system deployment; and combinations with fluoroscopy or radiographic systems. Current hosting, service, security, availability, and site configuration remain unverified.
  • Exact FDA submission
  • Checked 2026-09-04

This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.

Integration
The FDA package explicitly describes DICOM network send and receive, stand-alone diagnostic or reporting workstations, Siemens angiography systems, and combination with fluoroscopy or radiographic systems.
  • Exact FDA submission
  • Checked 2026-09-04

This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

Security
Siemens Healthineers' corporate cybersecurity page states a Secure Development Lifecycle addressing pre-market and post-market phases for products under development and a range of existing offerings; a Cybersecurity Management Service maintaining a product security inventory (over 1,000 product versions and over 21,000 monitored software components) with security whitepapers, SBOMs and vulnerability assessments available to customers via teamplay Fleet; incident and vulnerability management channels; and that Siemens Healthineers AG maintains an independent certification of its global Cybersecurity Management System to ISO/IEC 27001:2022 extended by ISO/IEC 27701:2019, with the certificate referenced to the SGS directory. Vendor statement; no certificate or report was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own corporate-info page names Siemens Medical Solutions USA, Inc. (Malvern, PA), and its 2024 governance press release states Siemens Healthcare GmbH's business was transferred to Siemens Healthineers AG. Corporate program statement; exact-release scope is not established.

Training
Only physicians and trained healthcare professionals responsible for diagnostic or interventional image review should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K170747 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Configured modalities, OEM options, procedures, hardware, and local workflow determine the available functions; the software does not replace qualified professional interpretation or procedural control.
  • Exact FDA submission
  • Checked 2026-09-04

This is buyer-facing monitoring guidance derived from the exact cleared or authorized scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K170747 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared or authorized release includes them.

Deployment boundary

The FDA package describes stand-alone diagnostic review, post-processing, and reporting workstations; network configuration; Siemens angiography-system deployment; and combinations with fluoroscopy or radiographic systems. Current hosting, service, security, availability, and site configuration remain unverified.

exact submission · checked 2026-09-04

FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The FDA package explicitly describes DICOM network send and receive, stand-alone diagnostic or reporting workstations, Siemens angiography systems, and combination with fluoroscopy or radiographic systems.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Configured modalities, OEM options, procedures, hardware, and local workflow determine the available functions; the software does not replace qualified professional interpretation or procedural control.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor K170747 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Configured modalities, OEM options, procedures, hardware, and local workflow determine the available functions; the software does not replace qualified professional interpretation or procedural control.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. multimodality medical-image viewing and interventional post-processing software limits remain submission-specific.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K170747
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiological images; modality varies or is not specified in FDA list
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Anatomy represented in supported medical images and interventional procedures
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2017-06-09
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
11Source classes checked
0Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads

One trial record was screened. It evaluates syngo DynaCT Sine Spin with an ARTIS icono system but does not identify the syngo Application Software VD20 configuration in K170747; the record is quarantined. The current discovery snapshot contains 0 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, fda pma record, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared or authorized configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) K170747: syngo Application Software

    U.S. Food and Drug Administration - Published 2017-06-09 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Siemens Healthineers: Cybersecurity

    Siemens Healthineers - Accessed 2026-10-26

    Scope: security

Research history

  1. K170747 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260316

CMN Capillary Function with Oncology Virtual Expert

Cercare Medical A/S

Authorized purpose: Cercare Neurosuite with Capillary Function and Oncology Virtual Expert processes CT or MR information to provide perfusion, tissue-blood-volume, diffusion, labeling, and quantification support for adult brain glioma workflows.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain
Decision
2026-06-22
FDA-cleared K252947

HistoSonics® Planning Tool

HistoSonics, Inc.

Authorized purpose: HistoSonics Planning Tool is a stand-alone visualization and comparison tool for CT and MR studies used to plan histotripsy target localization, treatment volume, acoustic path, and patient position.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Liver; kidneys; lungs; ribs; and skin
Decision
2026-05-29
FDA-cleared K252261

InferCare RECIST

Beijing Infervision Healthcare Medical Technology Co., Ltd.

Authorized purpose: InferCare RECIST is a post-processing application for longitudinal medical-image display, lesion measurement, registration, tracking, segmentation, three-dimensional reconstruction, and RECIST reporting by trained professionals.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Tumors and lesions in adult patients age 21 and older
Decision
2026-03-13
FDA-cleared K254016

MI View&GO

Siemens Medical Solutions USA, Inc.

Authorized purpose: MI View&GO is a medical diagnostic application for viewing, manipulating, quantifying, analyzing, and comparing PET, nuclear-medicine, CT, and MR images across one or more time points, including labeled oncology, cardiology, neurology, organ-function, and radiotherapy-planning workflows.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Whole body, organs, tumors, heart, brain, and oncology regions
Decision
2026-02-10

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history